FDA OKs Keytruda Combo for Lung Cancer

May 11, 2017

The U.S. FDA has approved Merck’s Keytruda in combination with chemotherapy for previously untreated advanced lung cancer.

This approval is being heralded as a “game-changer” for Keytruda, solidifying Merck’s position in the oncology market. The approval was based on data from a study of 123 previously untreated patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

Keytruda carries a host of previous approvals for treating lung, head and neck cancers, melanoma, and, most recently, blood cancer.

Read the press release